WO2010089506A1 - Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met - Google Patents
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met Download PDFInfo
- Publication number
- WO2010089506A1 WO2010089506A1 PCT/FR2010/050177 FR2010050177W WO2010089506A1 WO 2010089506 A1 WO2010089506 A1 WO 2010089506A1 FR 2010050177 W FR2010050177 W FR 2010050177W WO 2010089506 A1 WO2010089506 A1 WO 2010089506A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzothiazol
- sulfanyl
- triazolo
- pyridazin
- radical
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 239000003112 inhibitor Substances 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title claims description 28
- 229940079593 drug Drugs 0.000 title abstract description 7
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title description 17
- 150000001556 benzimidazoles Chemical class 0.000 title description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 79
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 73
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 65
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 60
- 150000003839 salts Chemical group 0.000 claims abstract description 43
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 41
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 39
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 27
- -1 cycloalkyl radical Chemical class 0.000 claims description 484
- 150000003254 radicals Chemical class 0.000 claims description 182
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 119
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 64
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 58
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 239000007787 solid Substances 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 39
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 37
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 150000007530 organic bases Chemical class 0.000 claims description 36
- 150000007522 mineralic acids Chemical class 0.000 claims description 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 35
- 150000007524 organic acids Chemical class 0.000 claims description 35
- 235000005985 organic acids Nutrition 0.000 claims description 33
- 150000007529 inorganic bases Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 30
- 239000011707 mineral Substances 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 125000005842 heteroatom Chemical group 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 23
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 18
- 102000001253 Protein Kinase Human genes 0.000 claims description 17
- 108060006633 protein kinase Proteins 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 8
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 239000000543 intermediate Substances 0.000 claims description 8
- 229910052721 tungsten Inorganic materials 0.000 claims description 8
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- KYGJLLIDEFVJAN-UHFFFAOYSA-N 1-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(oxetan-3-yl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NC1COC1 KYGJLLIDEFVJAN-UHFFFAOYSA-N 0.000 claims description 6
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- PEULEMHOAZVOPX-UHFFFAOYSA-N n-[6-[(6-cyclopentyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(SC1=C2)=NC1=CC=C2SC(N1N=2)=NN=C1C=CC=2OC1CCCC1 PEULEMHOAZVOPX-UHFFFAOYSA-N 0.000 claims description 6
- IROIMHKBAROXIV-UHFFFAOYSA-N n-[6-[[6-(cyclohexylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(SC1=C2)=NC1=CC=C2SC(N1N=2)=NN=C1C=CC=2NC1CCCCC1 IROIMHKBAROXIV-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- JYWIJVKMDHZVFX-UHFFFAOYSA-N 1-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCOCC1 JYWIJVKMDHZVFX-UHFFFAOYSA-N 0.000 claims description 5
- LGNFHZSQZPLCIW-UHFFFAOYSA-N 1-[6-[[6-(cyclohexylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(NC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCCC1 LGNFHZSQZPLCIW-UHFFFAOYSA-N 0.000 claims description 5
- VKNWVBATMNUCHN-UHFFFAOYSA-N 6-[(6-cycloheptyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCCC1 VKNWVBATMNUCHN-UHFFFAOYSA-N 0.000 claims description 5
- KIARRTQIYAQPRT-UHFFFAOYSA-N 6-[(6-cyclopentyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCC1 KIARRTQIYAQPRT-UHFFFAOYSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- GNBZJBNGBVGERF-UHFFFAOYSA-N n-[6-[(6-cycloheptyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCCC1 GNBZJBNGBVGERF-UHFFFAOYSA-N 0.000 claims description 5
- VWFGHRABAYAHHF-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-2-(cyclopropylamino)acetamide Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)CNC1CC1 VWFGHRABAYAHHF-UHFFFAOYSA-N 0.000 claims description 5
- DBPMDXZKBHIJEP-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 DBPMDXZKBHIJEP-UHFFFAOYSA-N 0.000 claims description 5
- AIKYPVVQNJARJD-UHFFFAOYSA-N n-[6-[[6-(cyclopropylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2NC1CC1 AIKYPVVQNJARJD-UHFFFAOYSA-N 0.000 claims description 5
- QFNVVFCYWAZVAM-UHFFFAOYSA-N n-[6-[[6-(cyclopropylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(SC1=C2)=NC1=CC=C2SC(N1N=2)=NN=C1C=CC=2NC1CC1 QFNVVFCYWAZVAM-UHFFFAOYSA-N 0.000 claims description 5
- MRFFMALERXPRTF-UHFFFAOYSA-N 1-[6-[[6-(cyclopropylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(NC5CC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCOCC1 MRFFMALERXPRTF-UHFFFAOYSA-N 0.000 claims description 4
- WEAGCVMVWQYSOL-HDJSIYSDSA-N O[C@H]1CC[C@@H](CC1)Nc1ccc2nnc(Sc3ccc4nc(NC(=O)C5CC5)sc4c3)n2n1 Chemical compound O[C@H]1CC[C@@H](CC1)Nc1ccc2nnc(Sc3ccc4nc(NC(=O)C5CC5)sc4c3)n2n1 WEAGCVMVWQYSOL-HDJSIYSDSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- FVWXKHHCDIGSFD-UHFFFAOYSA-N n-[6-[(6-cyclopentyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCC1 FVWXKHHCDIGSFD-UHFFFAOYSA-N 0.000 claims description 4
- MEKRSGSNCPFBOF-MLGOLLRUSA-N n-[6-[[6-[(1r,2r)-2-methylcyclopentyl]oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C[C@@H]1CCC[C@H]1OC1=NN2C(SC=3C=C4SC(NC(=O)C5CC5)=NC4=CC=3)=NN=C2C=C1 MEKRSGSNCPFBOF-MLGOLLRUSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- XEQZNECFJPBGBF-UHFFFAOYSA-N 1-[6-[(6-cyclobutyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCOCC1 XEQZNECFJPBGBF-UHFFFAOYSA-N 0.000 claims description 3
- OUPAZYSGGFYNSE-UHFFFAOYSA-N 1-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(3-morpholin-4-ylpropyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCCN1CCOCC1 OUPAZYSGGFYNSE-UHFFFAOYSA-N 0.000 claims description 3
- VBIKDDWKDFQSGC-UHFFFAOYSA-N 1-[6-[[6-(cyclohexylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(NC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCOCC1 VBIKDDWKDFQSGC-UHFFFAOYSA-N 0.000 claims description 3
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 3
- KKZLAOWDYNMKRA-UHFFFAOYSA-N C1(CCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 Chemical compound C1(CCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 KKZLAOWDYNMKRA-UHFFFAOYSA-N 0.000 claims description 3
- AEQZFSMHMTUGJX-UHFFFAOYSA-N C1(CCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(CCOC)=O)C=C1 Chemical compound C1(CCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(CCOC)=O)C=C1 AEQZFSMHMTUGJX-UHFFFAOYSA-N 0.000 claims description 3
- GTQMNVDSBWUXEV-UHFFFAOYSA-N C1(CCCCC1)NC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(=O)NCCCN1CCOCC1)C=C2 Chemical compound C1(CCCCC1)NC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(=O)NCCCN1CCOCC1)C=C2 GTQMNVDSBWUXEV-UHFFFAOYSA-N 0.000 claims description 3
- SSKHTAGJCGWOFJ-UHFFFAOYSA-N C1(CCCCCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 Chemical compound C1(CCCCCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 SSKHTAGJCGWOFJ-UHFFFAOYSA-N 0.000 claims description 3
- SBEOEFCBBKFUAZ-UHFFFAOYSA-N C12CC(CC2C1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 Chemical compound C12CC(CC2C1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 SBEOEFCBBKFUAZ-UHFFFAOYSA-N 0.000 claims description 3
- URPDLGXNTLEUDU-UHFFFAOYSA-N C12CC(CC2C1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CCC2)C=C1 Chemical compound C12CC(CC2C1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CCC2)C=C1 URPDLGXNTLEUDU-UHFFFAOYSA-N 0.000 claims description 3
- OQGPRWYWXPZXKE-IYARVYRRSA-N C[C@@H]1CC[C@H](CC1)OC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(=O)NCCN1CCOCC1)C=C2 Chemical compound C[C@@H]1CC[C@H](CC1)OC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(=O)NCCN1CCOCC1)C=C2 OQGPRWYWXPZXKE-IYARVYRRSA-N 0.000 claims description 3
- NKOJGLFGOAPITN-IRXDYDNUSA-N C[C@@H]1C[C@H](CC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)NCCN2CCOCC2)C=C1 Chemical compound C[C@@H]1C[C@H](CC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)NCCN2CCOCC2)C=C1 NKOJGLFGOAPITN-IRXDYDNUSA-N 0.000 claims description 3
- MUBHKROTDUXLCY-ROUUACIJSA-N C[C@@H]1C[C@H](CCC1)OC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(=O)NCCN1CCOCC1)C=C2 Chemical compound C[C@@H]1C[C@H](CCC1)OC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(=O)NCCN1CCOCC1)C=C2 MUBHKROTDUXLCY-ROUUACIJSA-N 0.000 claims description 3
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 3
- IAHVYHLFGULNOM-DGCLKSJQSA-N F[C@H]1[C@@H](CCCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)N)C=C1 Chemical compound F[C@H]1[C@@H](CCCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)N)C=C1 IAHVYHLFGULNOM-DGCLKSJQSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- WNOXSJYMGFZFTQ-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(SC1=C2)=NC1=CC=C2SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 WNOXSJYMGFZFTQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- DEOUZFWSQWEPGE-UHFFFAOYSA-N 2-methylheptanamide Chemical compound CCCCCC(C)C(N)=O DEOUZFWSQWEPGE-UHFFFAOYSA-N 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 210000004324 lymphatic system Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003584 mesangial cell Anatomy 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- XGUSXMKMAIGTTA-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-methoxyazetidine-1-carboxamide Chemical compound C1C(OC)CN1C(=O)NC(SC1=C2)=NC1=CC=C2SC1=NN=C2N1N=C(OC1CCCCC1)C=C2 XGUSXMKMAIGTTA-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- WJVSRKSBRYAKIY-UHFFFAOYSA-N C1(CC1)NC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(CN(C)C)=O)C=C2 Chemical compound C1(CC1)NC=1C=CC=2N(N1)C(=NN2)SC2=CC1=C(N=C(S1)NC(CN(C)C)=O)C=C2 WJVSRKSBRYAKIY-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000047 product Substances 0.000 description 143
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 132
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- 238000001819 mass spectrum Methods 0.000 description 73
- 239000000203 mixture Substances 0.000 description 66
- 150000001875 compounds Chemical class 0.000 description 64
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 52
- 239000000843 powder Substances 0.000 description 47
- 239000003643 water by type Substances 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 35
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 239000002904 solvent Substances 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 28
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 24
- 235000019796 monopotassium phosphate Nutrition 0.000 description 24
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 24
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 229940093915 gynecological organic acid Drugs 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 235000010755 mineral Nutrition 0.000 description 20
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 20
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 239000000377 silicon dioxide Substances 0.000 description 16
- 238000006722 reduction reaction Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- FVNSRFMQXKMHTQ-UHFFFAOYSA-N (2-amino-1,3-benzothiazol-6-yl) thiocyanate Chemical compound C1=C(SC#N)C=C2SC(N)=NC2=C1 FVNSRFMQXKMHTQ-UHFFFAOYSA-N 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 229910052786 argon Inorganic materials 0.000 description 11
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000012429 reaction media Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000013877 carbamide Nutrition 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- MMPMUQZIGRNCIK-UHFFFAOYSA-N 3-chloro-n-cyclohexyl-[1,2,4]triazolo[4,3-b]pyridazin-6-amine Chemical compound N=1N2C(Cl)=NN=C2C=CC=1NC1CCCCC1 MMPMUQZIGRNCIK-UHFFFAOYSA-N 0.000 description 8
- IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical class CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- KZLFKBSRGMYSGY-UHFFFAOYSA-N 1-(2-morpholin-4-ylethyl)-3-(6-sulfanyl-1,3-benzothiazol-2-yl)urea Chemical compound S1C2=CC(S)=CC=C2N=C1NC(=O)NCCN1CCOCC1 KZLFKBSRGMYSGY-UHFFFAOYSA-N 0.000 description 7
- 108020001305 NR1 subfamily Proteins 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 7
- 238000000105 evaporative light scattering detection Methods 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- SLOPQIDPYOIJBV-UHFFFAOYSA-N 6-[(6-cyclobutyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCC1 SLOPQIDPYOIJBV-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- YHVQNULRPMZYEO-UHFFFAOYSA-N 3,6-dichloro-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound C1=CC(Cl)=NN2C(Cl)=NN=C21 YHVQNULRPMZYEO-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- UDRPGLMUPSCSAH-UHFFFAOYSA-N n-(6-sulfanyl-1,3-benzothiazol-2-yl)cyclopropanecarboxamide Chemical compound S1C2=CC(S)=CC=C2N=C1NC(=O)C1CC1 UDRPGLMUPSCSAH-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
- KGAPUVWAGYTGEK-UHFFFAOYSA-N 1-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCCC1 KGAPUVWAGYTGEK-UHFFFAOYSA-N 0.000 description 4
- CVZCYTQCYDQBNK-UHFFFAOYSA-N 6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 CVZCYTQCYDQBNK-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 4
- 238000000469 dry deposition Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- BPCGWBRPAHDORW-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-2-oxa-6-azaspiro[3.3]heptane-6-carboxamide Chemical compound C1C2(COC2)CN1C(=O)NC(SC1=C2)=NC1=CC=C2SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 BPCGWBRPAHDORW-UHFFFAOYSA-N 0.000 description 4
- OQTGGNDHAYETAT-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-methoxypropanamide Chemical compound C1=C2SC(NC(=O)CCOC)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 OQTGGNDHAYETAT-UHFFFAOYSA-N 0.000 description 4
- RIDRAVGAULSNLI-UHFFFAOYSA-N n-[6-[[6-(cyclohexylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2NC1CCCCC1 RIDRAVGAULSNLI-UHFFFAOYSA-N 0.000 description 4
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 4
- ZKBFVQGSCTZQMY-UHFFFAOYSA-N phenyl n-(6-thiocyanato-1,3-benzothiazol-2-yl)carbamate Chemical compound N=1C2=CC=C(SC#N)C=C2SC=1NC(=O)OC1=CC=CC=C1 ZKBFVQGSCTZQMY-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- PJOAZAUXVPXEFP-UHFFFAOYSA-N (2-bromo-1,3-benzothiazol-6-yl) thiocyanate Chemical compound C1=C(SC#N)C=C2SC(Br)=NC2=C1 PJOAZAUXVPXEFP-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-OYDXRQHMSA-N 1-[(2r,4s,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H]([14CH2]O)[C@@H](O)C1 IQFYYKKMVGJFEH-OYDXRQHMSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QKNFFJHHPCWXTH-UHFFFAOYSA-N 2-(methylamino)propanamide Chemical compound CNC(C)C(N)=O QKNFFJHHPCWXTH-UHFFFAOYSA-N 0.000 description 3
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 3
- AWUXKCVBLRNGHP-UHFFFAOYSA-N 6-[[6-(cyclopropylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2NC1CC1 AWUXKCVBLRNGHP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- LQAWVVCVQBLGAY-XYPYZODXSA-N Nc1nc2ccc(Sc3nnc4ccc(N[C@H]5CC[C@H](O)CC5)nn34)cc2s1 Chemical compound Nc1nc2ccc(Sc3nnc4ccc(N[C@H]5CC[C@H](O)CC5)nn34)cc2s1 LQAWVVCVQBLGAY-XYPYZODXSA-N 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- VHGXAHBIPPSLKO-UHFFFAOYSA-N [2-(2-morpholin-4-ylethylcarbamoylamino)-1,3-benzothiazol-6-yl] thiocyanate Chemical compound N=1C2=CC=C(SC#N)C=C2SC=1NC(=O)NCCN1CCOCC1 VHGXAHBIPPSLKO-UHFFFAOYSA-N 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- MSVXWCLBWNYODJ-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-2-methoxyacetamide Chemical compound C1=C2SC(NC(=O)COC)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 MSVXWCLBWNYODJ-UHFFFAOYSA-N 0.000 description 3
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 125000002755 pyrazolinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VBTWSMPFFTZRBM-UHFFFAOYSA-N 1-[6-[(6-cycloheptyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCOCC1 VBTWSMPFFTZRBM-UHFFFAOYSA-N 0.000 description 2
- RYHNTNMTTQVELV-UHFFFAOYSA-N 1-[6-[(6-cyclopentyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)NCCN1CCOCC1 RYHNTNMTTQVELV-UHFFFAOYSA-N 0.000 description 2
- NKOJGLFGOAPITN-UHFFFAOYSA-N 1-[6-[[6-(3-methylcyclopentyl)oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C1C(C)CCC1OC1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 NKOJGLFGOAPITN-UHFFFAOYSA-N 0.000 description 2
- RVJRDSFHFLFAGM-VQIMIIECSA-N 1-[6-[[6-[(1r,2r)-2-methylcyclopentyl]oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C[C@@H]1CCC[C@H]1OC1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 RVJRDSFHFLFAGM-VQIMIIECSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DRLMMVPCYXFPEP-UHFFFAOYSA-N 2-bromo-1,3-benzothiazole Chemical class C1=CC=C2SC(Br)=NC2=C1 DRLMMVPCYXFPEP-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- RNKRLKFVALLSJS-UHFFFAOYSA-N 3-chloro-6-cycloheptyloxy-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N=1N2C(Cl)=NN=C2C=CC=1OC1CCCCCC1 RNKRLKFVALLSJS-UHFFFAOYSA-N 0.000 description 2
- IIJQJXSWZMHLLU-UHFFFAOYSA-N 3-chloro-n-cyclohexyl-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-amine Chemical compound N=1N2C(Cl)=NN=C2CCC=1NC1CCCCC1 IIJQJXSWZMHLLU-UHFFFAOYSA-N 0.000 description 2
- MNQIPLFCOOLIHY-UHFFFAOYSA-N 3-chloro-n-cyclopropyl-[1,2,4]triazolo[4,3-b]pyridazin-6-amine Chemical compound N=1N2C(Cl)=NN=C2C=CC=1NC1CC1 MNQIPLFCOOLIHY-UHFFFAOYSA-N 0.000 description 2
- JSMDUOFOPDSKIQ-UHFFFAOYSA-N 3-methoxypropanoyl chloride Chemical compound COCCC(Cl)=O JSMDUOFOPDSKIQ-UHFFFAOYSA-N 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 2
- QPJUZOIYYUDCFN-UHFFFAOYSA-N 6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-2-(3-methoxyazetidin-1-yl)-1,3-benzothiazole Chemical compound C1(CCCCC1)OC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)N2CC(C2)OC)C=C1 QPJUZOIYYUDCFN-UHFFFAOYSA-N 0.000 description 2
- VTFRUWYVLDCBBN-UHFFFAOYSA-N 6-[[6-(cyclohexylamino)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1CCC=2NC1CCCCC1 VTFRUWYVLDCBBN-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KBWQMERCNOMYPB-UHFFFAOYSA-N C1(CCC1)NC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 Chemical compound C1(CCC1)NC=1C=CC=2N(N=1)C(=NN=2)SC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1 KBWQMERCNOMYPB-UHFFFAOYSA-N 0.000 description 2
- LXZLLMLPDOALIF-JOCQHMNTSA-N CC(=O)Nc1nc2ccc(Sc3nnc4ccc(N[C@H]5CC[C@H](O)CC5)nn34)cc2s1 Chemical compound CC(=O)Nc1nc2ccc(Sc3nnc4ccc(N[C@H]5CC[C@H](O)CC5)nn34)cc2s1 LXZLLMLPDOALIF-JOCQHMNTSA-N 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZDNWBQZVFKRBMY-UHFFFAOYSA-N [2-(2-pyrrolidin-1-ylethylcarbamoylamino)-1,3-benzothiazol-6-yl] thiocyanate Chemical compound N=1C2=CC=C(SC#N)C=C2SC=1NC(=O)NCCN1CCCC1 ZDNWBQZVFKRBMY-UHFFFAOYSA-N 0.000 description 2
- NQCMZGIMGJVHIH-UHFFFAOYSA-N [2-(morpholine-4-carbonylamino)-1,3-benzothiazol-6-yl] thiocyanate Chemical compound N=1C2=CC=C(SC#N)C=C2SC=1NC(=O)N1CCOCC1 NQCMZGIMGJVHIH-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- OTGHWLKHGCENJV-UHFFFAOYSA-N glycidic acid Chemical compound OC(=O)C1CO1 OTGHWLKHGCENJV-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- GTJVHXKDBZPSCB-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-2-(dimethylamino)acetamide Chemical compound C1=C2SC(NC(=O)CN(C)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 GTJVHXKDBZPSCB-UHFFFAOYSA-N 0.000 description 2
- OMFHJOJOAWDZAH-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-2-cyclopropylacetamide Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NC(=O)CC1CC1 OMFHJOJOAWDZAH-UHFFFAOYSA-N 0.000 description 2
- SRAONCCYALCDDD-UHFFFAOYSA-N n-[6-[[6-(3-methylcyclopentyl)oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical class C1C(C)CCC1OC1=NN2C(SC=3C=C4SC(NC(=O)C5CC5)=NC4=CC=3)=NN=C2C=C1 SRAONCCYALCDDD-UHFFFAOYSA-N 0.000 description 2
- CLKBSZZAPVMJOO-UHFFFAOYSA-N n-[6-[[6-(cyclopropylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-methoxypropanamide Chemical compound C1=C2SC(NC(=O)CCOC)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2NC1CC1 CLKBSZZAPVMJOO-UHFFFAOYSA-N 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 101150009274 nhr-1 gene Proteins 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- FOXXAQRNEIMDEC-UHFFFAOYSA-N phenyl n-phenoxycarbonylcarbamate Chemical compound C=1C=CC=CC=1OC(=O)NC(=O)OC1=CC=CC=C1 FOXXAQRNEIMDEC-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BVIJQMCYYASIFP-PHDIDXHHSA-N (1r,2r)-2-methylcyclopentan-1-ol Chemical compound C[C@@H]1CCC[C@H]1O BVIJQMCYYASIFP-PHDIDXHHSA-N 0.000 description 1
- BVIJQMCYYASIFP-NTSWFWBYSA-N (1r,2s)-2-methylcyclopentan-1-ol Chemical compound C[C@H]1CCC[C@H]1O BVIJQMCYYASIFP-NTSWFWBYSA-N 0.000 description 1
- VEALHWXMCIRWGC-NTSWFWBYSA-N (1r,3s)-3-methylcyclopentan-1-ol Chemical compound C[C@H]1CC[C@@H](O)C1 VEALHWXMCIRWGC-NTSWFWBYSA-N 0.000 description 1
- HTSABYAWKQAHBT-BQBZGAKWSA-N (1s,3s)-3-methylcyclohexan-1-ol Chemical compound C[C@H]1CCC[C@H](O)C1 HTSABYAWKQAHBT-BQBZGAKWSA-N 0.000 description 1
- VEALHWXMCIRWGC-WDSKDSINSA-N (1s,3s)-3-methylcyclopentan-1-ol Chemical class C[C@H]1CC[C@H](O)C1 VEALHWXMCIRWGC-WDSKDSINSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NCBWZAKJAXARDR-UHFFFAOYSA-N (3-amino-4-nitrophenyl) thiocyanate Chemical compound NC1=CC(SC#N)=CC=C1[N+]([O-])=O NCBWZAKJAXARDR-UHFFFAOYSA-N 0.000 description 1
- 0 *N(C(O*)=O)c([s]c1c2)nc1ccc2SC#N Chemical compound *N(C(O*)=O)c([s]c1c2)nc1ccc2SC#N 0.000 description 1
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 1
- OQGPRWYWXPZXKE-UHFFFAOYSA-N 1-[6-[[6-(4-methylcyclohexyl)oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C1CC(C)CCC1OC1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 OQGPRWYWXPZXKE-UHFFFAOYSA-N 0.000 description 1
- YXDIWVYPTOHFDJ-UHFFFAOYSA-N 1-aminocyclohexan-1-ol;hydrochloride Chemical compound Cl.NC1(O)CCCCC1 YXDIWVYPTOHFDJ-UHFFFAOYSA-N 0.000 description 1
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
- YKNUXXRRPRLOBW-UHFFFAOYSA-N 1-azaspiro[3.3]heptane Chemical compound C1CCC21NCC2 YKNUXXRRPRLOBW-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WUEHSFSWKSCHCK-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-ium-1-yl)acetate Chemical compound CCN1CCN(CC(O)=O)CC1 WUEHSFSWKSCHCK-UHFFFAOYSA-N 0.000 description 1
- MVAXDKDOPWPFML-UHFFFAOYSA-N 2-(dimethylamino)acetyl chloride;hydrochloride Chemical compound [Cl-].C[NH+](C)CC(Cl)=O MVAXDKDOPWPFML-UHFFFAOYSA-N 0.000 description 1
- LSDBHHOICLCJIL-UHFFFAOYSA-N 2-amino-2-cyclopropylacetamide Chemical compound NC(=O)C(N)C1CC1 LSDBHHOICLCJIL-UHFFFAOYSA-N 0.000 description 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- VDEJXKBCCWFYRL-UHFFFAOYSA-N 2-morpholin-4-ylethylurea Chemical compound NC(=O)NCCN1CCOCC1 VDEJXKBCCWFYRL-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- CBHTTYDJRXOHHL-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridazine Chemical class N1=NC=CC2=C1N=NN2 CBHTTYDJRXOHHL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VHQCBSZJSOOPBX-UHFFFAOYSA-N 3-amino-4-nitrobenzenethiol Chemical compound NC1=CC(S)=CC=C1[N+]([O-])=O VHQCBSZJSOOPBX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FCDZYDOVSLXWBC-UHFFFAOYSA-N 3-chloro-6-(3-methylcyclopentyl)oxy-[1,2,4]triazolo[4,3-b]pyridazine Chemical class C1C(C)CCC1OC1=NN2C(Cl)=NN=C2C=C1 FCDZYDOVSLXWBC-UHFFFAOYSA-N 0.000 description 1
- LNCXTENBJJENFO-IUCAKERBSA-N 3-chloro-6-[(1s,3s)-3-methylcyclohexyl]oxy-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound C1[C@@H](C)CCC[C@@H]1OC1=NN2C(Cl)=NN=C2C=C1 LNCXTENBJJENFO-IUCAKERBSA-N 0.000 description 1
- ZOFCWXMYRPYQJC-UHFFFAOYSA-N 3-chloro-6-cyclobutyloxy-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N=1N2C(Cl)=NN=C2C=CC=1OC1CCC1 ZOFCWXMYRPYQJC-UHFFFAOYSA-N 0.000 description 1
- TYQPJNNJSVTXBY-UHFFFAOYSA-N 3-chloro-6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N=1N2C(Cl)=NN=C2C=CC=1OC1CCCCC1 TYQPJNNJSVTXBY-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KSXGQRBTBLQJEF-UHFFFAOYSA-N 3-methoxyazetidine;hydrochloride Chemical compound Cl.COC1CNC1 KSXGQRBTBLQJEF-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- OLFRPICWUSXXFR-UHFFFAOYSA-N 6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-n-(2-pyrrolidin-1-ylethyl)-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=C(SC=3N4N=C(OC5CCCCC5)C=CC4=NN=3)C=C2SC=1NCCN1CCCC1 OLFRPICWUSXXFR-UHFFFAOYSA-N 0.000 description 1
- ASGZFLFETJQAQU-UHFFFAOYSA-N 6-[[6-(3-bicyclo[3.1.0]hexanyloxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=CC(OC2CC3CC3C2)=NN2C(SC3=CC=C4N=C(SC4=C3)N)=NN=C21 ASGZFLFETJQAQU-UHFFFAOYSA-N 0.000 description 1
- UYPMOGAKXAKWJK-UHFFFAOYSA-N 6-[[6-(cyclohexylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2NC1CCCCC1 UYPMOGAKXAKWJK-UHFFFAOYSA-N 0.000 description 1
- UPQYLMDIPZBYEP-UHFFFAOYSA-N 6-[[6-[4-(trifluoromethyl)cyclohexyl]oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-amine Chemical compound C1=C2SC(N)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCC(C(F)(F)F)CC1 UPQYLMDIPZBYEP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DSBRJZIRLZUHQD-ZKCHVHJHSA-N O[C@H]1CC[C@@H](CC1)Nc1ccc2nnc(Cl)n2n1 Chemical compound O[C@H]1CC[C@@H](CC1)Nc1ccc2nnc(Cl)n2n1 DSBRJZIRLZUHQD-ZKCHVHJHSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102000009203 Sema domains Human genes 0.000 description 1
- 108050000099 Sema domains Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YRACHDVMKITFAZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-b]pyridazine Chemical compound C1=CC=NN2C=NN=C21 YRACHDVMKITFAZ-UHFFFAOYSA-N 0.000 description 1
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 1
- DKBDGUZHUPTNFY-UHFFFAOYSA-N [2-(cyclopropanecarbonylamino)-1,3-benzothiazol-6-yl] thiocyanate Chemical compound N=1C2=CC=C(SC#N)C=C2SC=1NC(=O)C1CC1 DKBDGUZHUPTNFY-UHFFFAOYSA-N 0.000 description 1
- GWVOUZZRXAZQDW-UHFFFAOYSA-N [6-[(6-cyclopentyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl] carbamate Chemical compound C(N)(OC=1SC2=C(N=1)C=CC(=C2)SC1=NN=C2N1N=C(C=C2)OC1CCCC1)=O GWVOUZZRXAZQDW-UHFFFAOYSA-N 0.000 description 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- QCRFMSUKWRQZEM-UHFFFAOYSA-N cycloheptanol Chemical compound OC1CCCCCC1 QCRFMSUKWRQZEM-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical class NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OPUAWDUYWRUIIL-UHFFFAOYSA-N methanedisulfonic acid Chemical compound OS(=O)(=O)CS(O)(=O)=O OPUAWDUYWRUIIL-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- CXDCAOJVWFTXCR-UHFFFAOYSA-N n-[6-[(6-cyclohexyloxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)sulfanyl]-1,3-benzothiazol-2-yl]-3-methylbutanamide Chemical compound C1=C2SC(NC(=O)CC(C)C)=NC2=CC=C1SC(N1N=2)=NN=C1C=CC=2OC1CCCCC1 CXDCAOJVWFTXCR-UHFFFAOYSA-N 0.000 description 1
- QWYYUSPJWAGMPQ-UHFFFAOYSA-N n-[6-[[6-(4-methylcyclohexyl)oxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1CC(C)CCC1OC1=NN2C(SC=3C=C4SC(NC(=O)C5CC5)=NC4=CC=3)=NN=C2C=C1 QWYYUSPJWAGMPQ-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 1
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- COEZWFYORILMOM-UHFFFAOYSA-M sodium 4-[(2,4-dihydroxyphenyl)diazenyl]benzenesulfonate Chemical class [Na+].OC1=CC(O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 COEZWFYORILMOM-UHFFFAOYSA-M 0.000 description 1
- WXFLIROEULQDMT-UHFFFAOYSA-M sodium;2-(diethylamino)acetate Chemical compound [Na+].CCN(CC)CC([O-])=O WXFLIROEULQDMT-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- HTSABYAWKQAHBT-UHFFFAOYSA-N trans 3-methylcyclohexanol Natural products CC1CCCC(O)C1 HTSABYAWKQAHBT-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to novel 6-O-cycloalkyl or -6-NH-cycloalkyl-triazolopyridazine-sulfanyl benzothiazole and benzimidazole derivatives, process for their preparation, novel intermediates obtained, their use as medicaments, and pharmaceutical compositions containing them. and the novel use of such 6-triazolopyridazin-sulfanyl benzothiazole and benzimidazole derivatives.
- the present invention relates more particularly to novel 6-O-cycloalkyl or 6-NH-cycloalkyl-triazolopyridazine-sulfanyl benzothiazole and benzimidazole derivatives, exhibiting anticancer activity, via the modulation of the activity of proteins, in particular kinases.
- protein kinases play an important role in the regulation of a wide variety of cellular processes, including metabolism, proliferation cell adhesion and motility, cell differentiation or cell survival, with some protein kinases playing a central role in the initiation, development and completion of cell cycle events.
- the present invention relates to novel derivatives with inhibitory effects vis-à-vis protein kinases.
- the products according to the present invention can thus notably be used for the prevention or the treatment of diseases that can be modulated by the inhibition of protein kinases.
- the products according to the present invention exhibit in particular an anticancer activity, via the modulation of the activity of kinases.
- kinases for which modulation of activity is desired MET as well as MET protein mutants are preferred.
- the present invention also relates to the use of said derivatives for the preparation of a medicament for the treatment of humans.
- one of the objects of the present invention is to provide compositions having anticancer activity, acting in particular vis-à-vis kinases.
- MET is preferred.
- MET or Hepatocyte Growth Factor Receptor
- HGF Hepatocyte Growth Factor
- MET is a receptor with tyrosine kinase activity expressed in particular by epithelial and endothelial cells.
- HGF Hepatocyte Growth Factor
- HGF is described as the specific ligand of MET.
- HGF is secreted by the mesenchymal cells and activates the MET receptor that moderates. As a consequence, the receptor autophosphorylates on tyrosines of catalytic domain Y1230, Y1234 and Y1235.
- MET stimulation by HGF induces proliferation, scattering (or dispersion), cell motility, resistance to apoptosis, invasion and angiogenesis.
- the present invention also relates to novel inhibitors of the MET protein kinase and its mutants, which can be used for anti-angiogenic treatment, in particular in oncology.
- Ra represents a radical -O-cycloalkyl, or a radical -NH-cycloalkyl all optionally substituted
- X represents S, SO or SO2;
- A represents NH or S;
- W represents a hydrogen atom; an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- a cycloalkyl radical or an alkyl radical, optionally substituted by a halogen atom or a cycloalkyl, NR3R4, alkoxy, hydroxy, phenyl, heteroaryl or heterocycloalkyl radical, themselves optionally substituted;
- R1 and R2 are such that one of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, a cycloalkyl radical, a heterocycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NR3R4, optionally substituted phenyl radicals or R1 and R2 radicals form with the atom; nitrogen to which they are attached a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms selected from O, S, N and NH, with the optional S possibly being in SO or SO2 form; this radical including the possible NH it contains being optionally substituted; with R3 and R4, which may be identical or different, represent a hydrogen atom, an alkyl radical, a cycloalkyl radical,
- R5 and R5 ' which may be identical or different, represent an alkyl or cycloalkyl radical containing at most 6 carbon atoms; alk represents an alkyl radical containing at most 4 carbon atoms; it being understood that W does not represent H when A represents S, X represents S, Ra represents the O-cyclohexyl radical or the unsubstituted NH-cyclohexyl radical and represents a double bond, said products of formula (I) being in all forms racemic isomers, enantiomers and diastereoisomers, as well as addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).
- Ra represents an optionally substituted -O-cycloalkyl radical or -NH-cycloalkyl radical
- X is S, SO or SO 2
- A is NH or S
- W represents a hydrogen atom, an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- a cycloalkyl radical or an alkyl radical optionally substituted by a halogen atom or a cycloalkyl radical, NR3R4, alkoxy, hydroxy, phenyl, heteroaryl, or heterocycloalkyl themselves optionally substituted;
- R1 and R2 are such that one of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, a cycloalkyl radical, a heterocycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NR3R4, optionally substituted phenyl radicals or R1 and R2 radicals form with the atom; nitrogen to which they are attached a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms selected from O, S, N and NH, with the optional S possibly being in SO or SO2 form, this radical including any NH that it contains being optionally substituted; with R3 and R4, which may be identical or different, represent a hydrogen atom, an alkyl radical, a cycloalkyl radical,
- R5 represents an alkyl or cycloalkyl radical containing at most 6 carbon atoms; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).
- the subject of the present invention is the products of formula (I) as defined above or below in which zzz , Ra and X have the values defined in any of the other claims and:
- A represents NH or S
- W represents a hydrogen atom; an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- R 1 and R 2 are such that one of R 1 and R 2 represents a hydrogen atom or an alkyl radical and the other of R 1 and R 2 represents a hydrogen atom or a cycloalkyl radical; a heterocycloalkyl radical or an alkyl radical optionally substituted with an alkoxy, heterocycloalkyl or NR3R4 radical; or R1 and R2 together with the nitrogen atom to which they are attached form a cyclic radical containing 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical including the optional NH it contains being optionally substituted;
- R 3 and R 4 which may be identical or different, represent a hydrogen atom or an alkyl radical or a heterocycloalkyl radical, all optionally substituted with one or more identical or different radicals chosen from alkoxy, heterocycloalkyl or NH 2, NHAIk radicals; or N (Alk) 2; or R3 and R4 together with the nitrogen atom to which they are attached form a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical including the optional NH it contains being optionally substituted; all the cycloalkyl, heterocycloalkyl and phenyl radicals as well as the cyclic radicals that can be formed by R1 and R2 or R3 and R4 with the nitrogen atom to which they are bonded, defined above, being optionally substituted by one or more radicals chosen from halogen atoms, hydroxyl, alkoxy, NH2, NHaIk,
- these radicals optionally containing one or more other heteroatoms selected from O, S, N and NH, with 1 any possible S possibly being in SO or SO2 form; these radicals, including any NH they contain, may therefore be optionally substituted, in particular with a radical chosen from alkyl, alkoxy, cycloalkyl or heterocycloalkyl, themselves optionally substituted with one or more radicals chosen from halogen atoms and radicals; alkyl, alkoxy, NH 2, NHAIk or N (Alk) 2;
- Ra represents a radical -O-cycloalkyl, or a radical -NH-cycloalkyl all optionally substituted
- X represents S, SO or SO2;
- A represents NH or S;
- W represents a hydrogen atom; an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- a cycloalkyl radical or an alkyl radical, optionally substituted by a radical NR3R4, alkoxy, hydroxy, phenyl, heteroaryl, or heterocycloalkyl, themselves optionally substituted;
- R1 and R2 are such that one of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, a cycloalkyl radical, or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NR3R4, optionally substituted phenyl radicals or else R1 and R2 form with the nitrogen atom to which they are attached a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical including the possible NH that it contains being optionally substituted; with R3 and R4, identical or different, represent a hydrogen atom, an alkyl radical, a cycloalkyl radical, a heteroaryl radical or a phenyl radical, all optionally substituted or else R3 and R
- R5 and R5 ' which may be identical or different, represent an alkyl or cycloalkyl radical containing at most 6 carbon atoms; alk represents an alkyl radical containing at most 4 carbon atoms; it being understood that W does not represent H when A represents S, X represents S, Ra represents the O-cyclohexyl radical or the unsubstituted NH-cyclohexyl radical and represents a double bond, said products of formula (I) being in all forms racemic isomers, enantiomers and diastereoisomers, as well as addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).
- Ra represents an optionally substituted -O-cycloalkyl radical or -NH-cycloalkyl radical
- X is S, SO or SO 2
- A is NH or S
- W represents a hydrogen atom, an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- a cycloalkyl radical or an alkyl radical, optionally substituted by a radical NR3R4, alkoxy, hydroxy, phenyl, heteroaryl, or heterocycloalkyl, themselves optionally substituted;
- R1 and R2 are such that one of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy, heteroaryl, heterocycloalkyl, NR3R4, optionally substituted phenyl radicals or R1 and R2 together with the nitrogen atom to which they are attached form a cyclic radical containing from 3 to 10 members; and optionally one or more other heteroatoms selected from O, S, N and NH, this radical including the optional NH it contains being optionally substituted; with R3 and R4, which may be identical or different, represent a hydrogen atom, an alkyl radical, a cycloalkyl radical, a heteroaryl radical or an optionally substituted phenyl radical or else R3 and R4
- R5 represents an alkyl or cycloalkyl radical containing at most 6 carbon atoms; said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastereoisomers, as well as addition salts with the inorganic and organic acids or with the inorganic and organic bases of said products of formula (I).
- A represents NH or S
- W represents a hydrogen atom; an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- R 1 and R 2 are such that one of R 1 and R 2 represents a hydrogen atom or an alkyl radical and the other of R 1 and R 2 represents a hydrogen atom or a cycloalkyl radical; or an alkyl radical optionally substituted with an alkoxy, heterocycloalkyl or NR3R4 radical; or R1 and R2 together with the nitrogen atom to which they are attached form a cyclic radical containing 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical including the optional NH it contains being optionally substituted; with NR3R4, such that R3 and R4, which are identical or different, represent a hydrogen atom or an alkyl radical or else R3 and R4 form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 members and, if appropriate, one or more other heteroatoms chosen from O, S, N and NH, this radical including the optional NH
- A represents NH or S
- W represents a hydrogen atom; an alkyl radical optionally substituted by a heterocycloalkyl radical or NR3R4; or the radical COR in which R represents:
- R 1 and R 2 are such that one of R 1 and R 2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R 1 and R 2 represents a hydrogen atom; , an alkyl radical optionally substituted with a heterocyclic radical or NR3R4, or else R1 and R2 form, with the nitrogen atom to which they are bonded, a cyclic radical optionally containing one or more other heteroatoms chosen from O, S, N and NH, this radical including the optional NH it contains being optionally substituted; with NR3R4, such that R3 and R4, which may be identical or different, represent a hydrogen atom or an alkyl radical or else R3 and R4 form, with the nitrogen atom to which they are bonded, a cyclic radical optionally containing one
- the subject of the present invention is the products of formula (I) as defined above or below, in which A represents NH, the substituents zzz , Ra, X and W being chosen from all the values defined for these radicals at any of the other claims, said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with mineral and organic acids or with the mineral and organic bases of said products. of formula (I).
- the subject of the present invention is the products of formula (I) as defined above or below, in which A represents S, the substituents zzz , Ra, X and W being chosen from among all the values defined for these radicals. any of the other claims, said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with mineral and organic acids or with the mineral and organic bases of said products. of formula (I).
- Ra and W are selected from the meaning indicated in any one of the other claims, said products of formula (Ia) and (Ib) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as salts addition with the mineral and organic acids or with the inorganic and organic bases of said products of formula (Ia) and (Ib).
- the subject of the present invention is the products of formula (I) as defined above or below, in which represents a single bond corresponding to the products of formula (I 1 ):
- the subject of the present invention is the products of formula (I) as defined above or below, in which represents a single bond corresponding to the products of formula (Ia '):
- Ra and W are selected from the meaning indicated in any one of the other claims, said products of formula (a) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with inorganic and organic acids or with the inorganic and organic bases of said products of formula (a).
- Ra and W are selected from the meaning indicated in any one of the other claims, said products of formula (I “a) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with inorganic and organic acids or with the inorganic and organic bases of said products of formula (I "a).
- the subject of the present invention is the products of formula (I) as defined above or hereinafter in which zzz represents a single bond corresponding to the products of formula (b):
- Ra and W are selected from the meaning indicated in any one of the other claims, said products of formula (b) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with the inorganic and organic acids or with the inorganic and organic bases of said products of formula (b).
- Ra and W are selected from the meaning indicated in any one of the other claims, said products of formula (I “b) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with inorganic and organic acids or with the inorganic and organic bases of said products of formula (I "b).
- alkyl radical denotes the radicals, linear and, if appropriate, branched, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and also heptyl, octyl, nonyl and decyl and their linear or branched positional isomers: alkyl radicals containing from 1 to 6 carbon atoms and more particularly radicals are preferred alkyl containing 1 to 4 carbon atoms from the above list;
- alkoxy radical denotes the linear and, if appropriate, branched, methoxy, ethoxy, propoxy, isopropoxy, linear butoxy, secondary or tertiary, pentoxy or hexoxy radicals, as well as their linear or branched positional isomers: the alkoxy radicals containing 1 to 4 carbon atoms from the above list;
- halogen atom denotes the chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom.
- cycloalkyl radical denotes a saturated carbocyclic radical containing 3 to 10 carbon atoms and thus particularly denotes the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals and especially the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals;
- heterocycloalkyl radical thus denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 members interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms; for example, morpholinyl, thiomorpholinyl, aziridyl, azetidyl, piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, oxodihydropyridazinyl radicals, or alternatively oxetanyl or thietanyl radicals, these radicals being optionally substituted; it may be noted that these heterocycloalkyl radicals may comprise a bridge formed from two links to form, for example, morpholin
- aryl and heteroaryl denote unsaturated or partially unsaturated, respectively carbocyclic and heterocyclic, monocyclic or bicyclic radicals, containing at most 12 members, which may optionally contain a -C (O) - chain, heterocyclic radicals containing one or more identical heteroatoms or different selected from O, N, or S with N, if appropriate, optionally substituted;
- aryl radical thus denotes monocyclic or bicyclic radicals containing 6 to 12 members, such as, for example, the phenyl, naphthyl, biphenyl, indenyl, fluorenyl and anthracenyl radicals, more particularly the phenyl and naphthyl radicals and even more particularly the phenyl radical.
- a carbocyclic radical containing a -C (O) - linkage is, for example, the tetralone radical;
- heteroaryl radical thus denotes monocyclic or bicyclic radicals containing 5 to 12 ring members: monocyclic heteroaryl radicals such as, for example, thienyl radicals such as 2-thienyl and 3-thienyl, furyl such as 2-furyl, 3-furyl, pyrannyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl such as 2-pyhdyl, 3-pyridyl and 4-pyhdyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, isothiazolyl, diazolyl, thiadiazolyl, thiatriazolyl, oxadiazolyl, isoxazolyl as 3- or 4-isoxazolyl, furazannyl, free or salt tetrazolyl,
- heteroaryl or bicyclic radicals there may be mentioned more particularly the pyrimidinyl, pyridyl, pyrrolyl, azaindolyl, indazolyl or pyrazolyl radicals, optionally substituted by one or more identical or different substituents as indicated above.
- the carboxyl group (s) of the products of formula (I) may be salified or esterified with the various groups known to those skilled in the art, among which may be mentioned, for example:
- mineral bases such as, for example, one equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxymethyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine , arginine, histidine, N-methylglucamine,
- the alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals being able to be substituted by radicals chosen, for example, from the atoms of halogen, hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals such as in groups chloromethyl, hydroxypropyl, methoxynethyl, propionyloxymethyl, methylthionethyl, dimethylanninoethyl, benzyl or phenethyl.
- the addition salts with the mineral or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulphonic acids such as, for example, methanesulfonic acid, ethanesulphonic acid, propanesulphonic acid, alkylsulphonic acids such as, for example, methanedisulfonic acid, alpha, beta-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulphonic acid and aryldisulphonic acids.
- hydrochloric hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic,
- stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but whose different groups are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent can be in axial or equatorial position, and the different possible rotational conformations of the ethane derivatives.
- stereoisomerism due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, often called geometric isomerism or cis-trans isomerism.
- stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.
- the cyclic radicals that R 1 and R 2 can form on the one hand with the nitrogen atom to which they are bonded and on the other hand R 3 and R 4 with the nitrogen atom to which they are bonded, are optionally substituted with one or several radicals chosen from those indicated above for the possible substituents of heterocycloalkyl radicals, ie one or more radicals selected from halogen atoms, hydroxyl, oxo, alkoxy, NH 2 radicals; NHaIk, N (alk) 2, and the radicals alkyl, heterocycloalkyl, CH2-heterocycloalkyl, phenyl, CH2-phenyl, heteroaryl, and CO-phenyl, such that in these latter radicals the alkyl, heterocycloalkyl and phenyl radicals are themselves optionally substituted with one or more radicals selected from halogen atoms and hydroxyl, oxo, alkyl and alkoxy radicals having 1 to 4 carbon atoms, NH
- the cyclic radicals that can be formed on the one hand R 1 and R 2 with the nitrogen atom to which they are bonded and on the other hand R 3 and R 4 with the nitrogen atom to which they are bonded, are in particular optionally substituted by a or more identical or different radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, CH 2 -pyrrolidinyl, CH 2 -phenyl, heteroaryl and phenyl radicals, in which the alkyl, pyrrolidinyl and phenyl radicals are themselves optionally substituted by one or more identical or different radicals chosen from halogen atoms and alkyl, hydroxyl, oxo and alkoxy radicals.
- heterocycloalkyl radicals as defined above represent, in particular, the azepanyl, morpholinyl and pyrrolidinyl, piperidyl and piperazinyl radicals themselves optionally substituted, as defined above or hereinafter.
- NR1 R2 or NR3R4 forms a ring as defined above
- such an amine ring may be chosen in particular from pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, azepinyl, morpholinyl or piperazinyl radicals, these radicals themselves being optionally substituted as indicated.
- radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, phenyl and CH 2 -phenyl radicals for example by one or more identical or different radicals chosen from halogen atoms and alkyl, hydroxyl, alkoxy, phenyl and CH 2 -phenyl radicals, the alkyl or phenyl radicals being themselves optionally substituted by one or several identical or different radicals chosen from halogen atoms and alkyl, hydroxyl and alkoxy radicals.
- the NR 1 R 2 or NR 3 R 4 ring may more particularly be chosen from pyrrolidinyl and morpholinyl radicals, optionally substituted by one or two alkyl or piperazinyl radicals, optionally substituted on the second nitrogen atom by an alkyl, phenyl or CH 2 -phenyl radical, themselves optionally substituted by one or more identical or different radicals chosen from halogen atoms and alkyl, hydroxyl and alkoxy radicals.
- Ra represents a -O-cycloalkyl radical, or a -NH-cycloalkyl radical optionally substituted with a hydroxyl, alkoxy or -O-CO-R5 radical;
- X is S; A represents S;
- W represents a hydrogen atom or an alkyl radical optionally substituted with heterocycloalkyl or the COR radical in which R represents:
- a cycloalkyl radical or an alkyl radical, optionally substituted with an NR 3 R 4 radical, or alkoxy radical; an O-phenyl radical;
- R1 and R2 are such that one represents a hydrogen atom and the other represents an alkyl radical optionally substituted with a heterocycloalkyl radical; with NR3R4 such that R3 and R4, which may be identical or different, represent a hydrogen atom or an alkyl radical; R5 represents an alkyl or cycloalkyl radical containing at most 6 carbon atoms; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).
- the cycloalkyl radicals may represent a cycloheptyl, cyclohexyl, cyclopentyl, cyclobutyl or cyclopropyl radical;
- heterocycloalkyl radicals may represent a morpholinyl or pyrrolidinyl radical.
- the subject of the present invention is also any process for the preparation of the products of formula (I) as defined above
- the subject of the present invention is thus any process for the preparation of the products of formula (I) as defined above in which A represents NH.
- the subject of the present invention is thus any process for the preparation of the products of formula (I) as defined above in which A represents S.
- the products according to the invention can be prepared from conventional methods of organic chemistry.
- Schemes 1, 2, 3, 4, 5 and 6 below are illustrative of the methods used for the preparation of the products of formula (I). As such, it can not constitute a limitation of the scope of the invention, as regards the methods of preparation of the claimed compounds.
- the products of formula (I) as defined above according to the present invention can thus be prepared in particular according to the processes described in Schemes 1, 2, 2bis, 3, 4, 5 and 6 below.
- the present invention thus also relates to the process for the preparation of products of formula (I) according to Scheme 1 as defined below.
- the present invention thus also relates to the process for preparing products of formula (I) according to Scheme 2 as defined below.
- the present invention thus also relates to the process for preparing products of formula (I) according to Scheme 2bis as defined below.
- the present invention thus also relates to the process for the preparation of products of formula (I) according to Scheme 3 as defined below
- the present invention thus also relates to the process for preparing products of formula (I) according to Scheme 4 as defined below
- the present invention thus also relates to the process for the preparation of products of formula (I) according to Scheme 5 as defined below
- the present invention thus also relates to the process for the preparation of products of formula (I) according to Scheme 6 as defined below
- the products of formula (V) which represent the products of formula (I) in which represents a bond are defined simple and the products of formula (I ") which represent the products of formula (I) in which zzz ⁇ represents a double bond, likewise for synthetic intermediates as defined below of formulas (a), (b) (c), (d), (e) and (f) wherein represents a single or double bond, the compounds of formulas (a 1 ), (b 1 ), (c 1 ), (d 1 ) are defined , (e 1 ) and (f) in which zzz ⁇ represents a single bond, and the compounds of formulas (a "), (b"), (c “), (d"), (e ") and (f) in which represents a double bond.
- the substituent Ra can take the meanings indicated above for the products of formula (I 1 ) and (I "), the substituent R 5, in the compounds of formulas (J), (1a). 1 ) and (1 a ") represents an alkyl radical and the substituent R 6 in the compounds of formulas (O), (1d ') and (1d") represents an alkyl radical optionally substituted with NR 3 R 4 (a radical - ( CH2) n-NR3R4), alkoxy, hydroxy, heterocycloalkyl, phenyl, - (CH2) n- phenyl, with optionally substituted phenyl and n represents an integer of 1 to 4.
- the substituent R 7 in the compounds of formulas (P) and (1 e ') / (1 e ") represents a cycloalkyl or alkyl radical optionally substituted with a radical NR3R4, alkoxy, hydroxy phenyl, heteroaryl, or heterocycloalkyl, themselves optionally substituted.
- the benzimidazoles of the general formula (1a “), (1b"), (1c “), (1d") and (1e ") and their reduced analogues of the general formula ( 1 to 1 ), (1 b 1 ), (1c '), (1cT) and (1 e 1 ) can be prepared from 3,6-dichloro [1,2,4] triazolo [4,3 commercial pyridazine of formula (S).
- the compounds (E) can be obtained, for example, by reacting alcohols or amines in the presence or absence of a base on the compound (S). The reaction is carried out, for example, at a temperature in the region of 20 ° C. to 80 ° C.
- Compounds (G) can be obtained, for example, by reaction of 3-amino-4-nitro-benzenethiol of formula (F) with compounds of formula (E).
- the compounds of formula (F) are obtained by in situ reduction of 3-amino-4-nitrophenyl thiocyanate (Q) (commercial compound), by for example, in the presence of sodium borohydride in a solvent such as N, N-dimethylformamide, at a temperature in the region of 20 ° C.
- the compounds (H ") as represented by a double bond can be obtained, for example, by reduction with iron (O) on the compounds of formula (G), in a solvent such as methanol, in the presence of acetic acid, at a temperature in the region of 70 ° C.
- the compounds (H ') such that zz 1 are a single bond can be obtained, for example, by reduction with zinc (O) on the compounds of formula (G), in the presence of acetic acid, at a temperature close to 20 ° C.
- the carbamates of general formula (1 a ') and (1 a ") can be prepared in particular as described in patent WO03028721A2, from a 3,4-diamino phenyl sulfide of formula (H') and (H ") and a pseudothiourea of formula (J), in the presence of acetic acid and in a protic solvent such as methanol, at a temperature of 80 0 C.
- the benzimidazoles of general formula (1b ') and (1b ") can be prepared respectively by reaction of an amine NHR1 R2 of formula (R) (with R1 and R2 as defined above) on a carbamate of formula (1 a ') and (1 a "), for example in the presence of an aprotic solvent such as 1-methyl-2-pyrrolidinone.
- the reaction is carried out, for example, a temperature close to 120 ° C., in a tube sealed under microwaves.
- the 2-amino benzimidazoles of general formula (1c ') and (1c ") can be prepared, for example, by reaction of cyanogen bromide with a compound of formula (H') and (H") respectively, in presence of a protic solvent such as ethanol. The reaction is carried out at a temperature in the region of 80 ° C.
- carboxamides (1 ') and (1e ") can be obtained respectively from the amines of general formula (1c') and (1c")
- the benzothiazoles of the general formula (2a "), (2b"), (2c ") and (2d") as well as their reduced analogues of the general formula (2a 1 ), (2b 1 ), (2c 1 ) and (2cT) can be prepared from 2-amino-1,3-benzothiazol-6-yl (K) thiocyanate (commercial compound).
- the carboxamides (L3) can be obtained by acylation of the amine (K)
- the glycidic acids (P ') can be prepared from bromoacetic acid and amines HNR3R4 under conditions similar to those described by D. T. Witiak et.al .; J. Med. Chem. 1985, 28, 1228.
- the amines (2d ') and (2d ") can be treated with chloroacetyl chloride in the presence of a base such as pyridine, triethylamine or N-methylmorpholine, in a solvent such as dichloromethane at a temperature in the region of 0 ° C. to 20 ° C.
- a base such as pyridine, triethylamine or N-methylmorpholine
- dichloromethane a temperature in the region of 0 ° C. to 20 ° C.
- the alpha-chloroacetamides (2e72e) thus formed can react with amines of the HNR3R4 type, as defined above, in a solvent such as pyridine at a temperature of 20 0 C, to give the derivatives (2c72c ") as defined in Scheme 2a above.
- the compounds of general formula (M1), (M2) and (M3) can be obtained, for example, by reduction of compounds of general formula (L1), (L2), (L3) with DL-dithiotreitol, in the presence of sodium dihydrogen carbonate in a solvent such as ethanol and at a temperature in the region of 80 ° C.
- the compound of general formula (N) can be prepared in situ by reduction of the compound of formula (K), for example with sodium borohydride in a solvent such as N, N-dimethylformamide, in the presence of a base such as triethylamine and at a temperature in the region of 95 ° C. or between 20 ° C. and 95 ° C.
- a chlorocarbonate of formula (O) (X Cl)
- the benzothiazoles of general formula (2a "), (2b"), (2c ") and (2d") as well as their reduced analogues of general formula (2a '), (2b 1 ), (2c 1 ) and (2d ') can be prepared for example: 1) or by coupling a compound of formula (E) with derivatives (M1), (M2) and (M3) and (N) generated in situ by reduction of derivatives (L1), (L2), (L3) and (K) with sodium borohydride, in a solvent such as N, N-dimethylformamide and in the presence of a base such as thylamine, at a temperature in the region of 95 ° C or between 50 ° C and 95 ° C .
- the substituent R8 represents a cycloalkyl radical as defined above for the products of formula (I)
- the compounds of formula (E) can be obtained, for example, as shown in scheme 3 above, from commercially available 3,6-dichloro [1,2,4] thazolo [4,3-b] pyridazine of formula (S).
- the compounds of formula (E) in which Ra represents an OR8 radical can be obtained by treatment of 3,6-dichloro [1,2,4] thazolo [4,3-b] pyridazine (S) at a temperature of a temperature of about 20 0 C to 80 0 C and in a solvent such as tetrahydrofuran with an alkoxide of formula (U), itself obtained by treatment of an alcohol (HOR8) with, for example, sodium hydride in a solvent such as tetrahydrofuran at a temperature in the region of 0 ° C. to 20 ° C.,
- the compounds of formula (E) wherein Ra represents an R8NH radical can be obtained by treatment of 3,6-dichloro [1,2,4] thazolo [4,3-b] pyhdazine (S) with a amine of formula (R8NH2), at a temperature in the region of 20 ° C to 50 ° C and in a solvent such as N, N-dimethylformamide.
- the benzothiazoles of general formula (2e 1 ) and (2e ") can be prepared respectively from the compounds of formulas (2a 1 ) and (2a").
- the substituent OR6 is preferably O-t-butyl.
- the substituent R 9 represents an alkyl or cycloalkyl radical optionally substituted with an alkoxy, heterocycloalkyl or NR 3 R 4 radical (R 3 and R 4 as defined above).
- the compounds of general formula (2e 1 ) and (2e ") can be obtained respectively by treatment of the compounds (T) and (T ") isolated, for example, with trifluoroacetic acid, in a solvent such as dichloromethane, at a temperature in the region of 20 ° C.,
- the compounds of general formula (2e ") can be obtained directly by reaction of the compounds of formula (L4) and (E), via the compound (T") formed in situ, for example, in the presence of DL-dithiotreitol and of sodium dihydrogen carbonate, in a solvent such as ethanol and at a temperature of about 80 ° C., optionally followed by an in situ treatment with trifluoroacetic acid at 20 ° C. if necessary.
- the carbamates of general formula (L4) can be obtained by reaction of carbamates of general formula (L1), for example with alkyl halides of formula (W), in a solvent such as N, N-dimethylformamide, in the presence sodium hydride, at a temperature of between 20 and 90 ° C.
- the benzothiazoles of general formula (2e ") can be prepared from the compounds of formulas (L6) and (E), for example, in the presence of DL-dithiotreitol and sodium dihydrogen carbonate in a solvent such as ethanol and at a temperature in the region of 80 ° C.
- the benzothiazoles of general formula (2e 1 ) can be prepared from compounds of formula (2e "), according to the methods described below for the preparation of compounds (I 1 ) from compounds (I").
- the compounds of formulas (L6) can be prepared from the 2-bromo benzothiazole derivative (L5) by treatment with an NH 2 R 9 derivative, for example, in a solvent such as tetrahydrofuran, at a temperature in the region of 20 ° C.
- the substituent R 9 represents an alkyl or cycloalkyl radical optionally substituted with an alkoxy, heterocycloalkyl or NR 3 R 4 radical (R 3 and R 4 as defined above).
- the compounds of formulas (L5) can be prepared from 2-amino-1,3-benzothiazol-6-yl (K) thiocyanate (commercial compound), for example by treatment with an alkyl nitrite and bromide. cuprous in a solvent such as acetonitrile, at a temperature of 0-20 ° C, according to the method described by Jagabandhu Das et. al. in J. Med. Chem. 2006, 49, 6819-6832.
- the benzothiazoles of general formula (T) may also be prepared, starting from the compounds of formula (I "), by reduction, for example, with sodium borohydride, in a solvent such as ethanol, at a temperature of about 80 0 C or by reduction with zinc (0) in the presence of acetic acid, at a temperature of 20 ° C.
- the compounds (I 1 ) can also be prepared from compounds of formula (E ') by coupling with compounds of type M1, M2, M3 or N, obtained as intermediates by reduction of compounds L1, L2. , L3 or K in situ, as described above in Scheme 2.
- the M1, M2 or M3 type compounds can also be isolated and used for coupling with (E ').
- the compounds (E ') can be obtained from the compounds of formula (E) by reduction, for example, by reduction with zinc (O) in the presence of acetic acid, at a temperature in the region of 20 ° C.
- the compounds (I ') may also be prepared from other compounds (T) by transformation of the group W into a group W of the same nature as defined above for W and according to the type of reactions defined in scheme 2: transformations of 2d '/ 2d "into 2a' / 2a" and into 2c '/ 2c ", the transformations of 2a' / 2a" into 2d '/ 2d "and into 2b' / 2b".
- sulfur S can be oxidized to sulfoxide SO or sulfone SO 2 according to the methods known to those skilled in the art and, if necessary, protecting the optionally reactive groups by appropriate protective groups.
- the hydroxyl groups may be protected, for example, by alkyl radicals such as tert-butyl, thmethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, benzyl or acetyl,
- amino groups may be protected for example by the acetyl, trityl, benzyl, tert-butoxycarbonyl, BOC, benzyloxycarbonyl, phthalimido or other radicals known in peptide chemistry,
- esters formed with easily cleavable esters such as benzyl or tert-butyl esters or esters known in peptide chemistry.
- intermediate products or products of formula (I) thus obtained can be subjected, if desired and if necessary, to the processes described above, to obtain other intermediates or other products of formula (I), one or more reactions of transformations known to those skilled in the art such as for example: a) an esterification reaction of acid function, b) a saponification reaction of ester function in acid function, c) a reduction reaction of the free or esterified carboxy function as a function of alcohol, d) an alkoxy function-to-hydroxyl function conversion reaction, or also an alkoxy-functional hydroxyl function, e) an elimination reaction of the protective groups that the protected reactive functions, f) a salification reaction with a mineral or organic acid or a base to obtain the corresponding salt, g) a resolving reaction of the racemic forms into split products, said products of formula (I) thus obtained being in any isomeric possible racemic, enantiomeric and diastereoisomeric forms.
- the saponification reaction can be carried out according to the usual methods known to those skilled in the art, such as, for example, in a solvent such as methanol or ethanol, dioxane or dimethoxyethane, in the presence of sodium hydroxide or potassium hydroxide.
- a solvent such as methanol or ethanol, dioxane or dimethoxyethane
- the optional free or esterified carboxy functions of the products described above may, if desired, be reduced in alcohol function by the methods known to those skilled in the art: the optional esterified carboxy functions may, if desired, be reduced depending on the alcohol by the methods known to those skilled in the art and in particular by lithium hydride and aluminum in a solvent such as for example tetrahydrofuran or dioxane or ethyl ether.
- the optional free carboxy functions of the products described above may, if desired, be reduced in particular alcohol function by boron hydride.
- the optional alkoxy functions, such as methoxy in particular, of the products described above may, if desired, be converted into hydroxyl function under the usual conditions known to those skilled in the art, for example by boron tribromide in a solvent such as For example, methylene chloride, with hydrobromide or pyridine hydrochloride or with hydrobromic or hydrochloric acid in water or trifluoroacetic acid under reflux.
- a solvent such as For example, methylene chloride, with hydrobromide or pyridine hydrochloride or with hydrobromic or hydrochloric acid in water or trifluoroacetic acid under reflux.
- the phthalimido group can be removed by hydrazine.
- the products described above may, if desired, be the subject of salification reactions, for example by a mineral or organic acid or by a mineral or organic base according to the usual methods known to those skilled in the art: such salification reaction can be carried out for example in the presence of hydrochloric acid for example or tartaric acid, citric or methanesulfonic acid in an alcohol such as for example ethanol or methanol.
- hydrochloric acid for example or tartaric acid, citric or methanesulfonic acid in an alcohol such as for example ethanol or methanol.
- the products of the present invention are especially useful for tumor therapy.
- the products of the invention can also increase the therapeutic effects of commonly used anti-tumor agents.
- the subject of the invention is, as medicaments, the products corresponding to the following formulas:
- the invention also relates to pharmaceutical compositions containing as active principle at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate, optionally, a pharmaceutically acceptable carrier.
- the invention thus extends to pharmaceutical compositions containing as active principle at least one of the drugs as defined above.
- compositions of the present invention may also, where appropriate, contain active ingredients of other antimitotic drugs such as in particular those based on taxol, cisplatin, intercalating DNA agents and others.
- compositions may be administered orally, parenterally or locally by topical application to the skin and mucous membranes or by intravenous or intramuscular injection.
- compositions may be solid or liquid and may be in any of the pharmaceutical forms commonly used in human medicine, such as, for example, simple or coated tablets, pills, lozenges, capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods.
- the active ingredient can be incorporated into the excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, the fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersing or emulsifying agents, preservatives.
- the usual dosage, variable according to the product used, the subject treated and the condition in question, may be, for example, from 0.05 to 5 g per day in the adult, or preferably from 0.1 to 2 g. per day.
- the subject of the present invention is also the use of the products of formula (I) as defined above or of pharmaceutically acceptable salts of these products for the preparation of a medicament intended for inhibiting the activity of a protein kinase.
- the subject of the present invention is also the use of products of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease characterized by the dysregulation of a protein kinase.
- a medicament may especially be intended for the treatment or prevention of a disease in a mammal.
- the present invention also relates to the use defined above in which the protein kinase is a protein tyrosine kinase.
- the subject of the present invention is also the use defined above in which the protein tyrosine kinase is MET or its mutant forms.
- the present invention also relates to the use defined above in which the protein kinase is in a cell culture.
- the present invention also relates to the use defined above in which the protein kinase is in a mammal.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the prevention or treatment of diseases related to uncontrolled proliferation.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment or prevention of a disease selected from the following group: disorders proliferation of blood vessels, fibrotic disorders, mesangial cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
- a disease selected from the following group: disorders proliferation of blood vessels, fibrotic disorders, mesangial cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
- the present invention thus particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment or prevention of diseases in oncology and in particular for treatment of cancers.
- the products of the present invention cited can in particular be used for the treatment of primary tumors and / or metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate, lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder, breast, melanoma, lymphoid or myeloid hematopoietic tumors, sarcomas, brain, larynx, lymphatic system, bone and pancreas.
- NSCLC and SCLC lung
- the subject of the present invention is also the use of the products of formula (I) as defined above for the preparation of medicaments intended for the chemotherapy of cancers.
- Such drugs for cancer chemotherapy may be used alone or in combination.
- the products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or in combination with other therapeutic agents, for example.
- Such therapeutic agents may be commonly used anti-tumor agents.
- kinase inhibitors there may be mentioned butyrolactone, flavopiridol and 2 (2-hydroxyethylamino) -6-benzylamino-9-methylpurine called olomucine.
- the subject of the present invention is also, as new industrial products, the synthetic intermediates of formulas E ', M1, M2, M3 and N as defined above and recalled hereinafter:
- the N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] tetrazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) cyclopropanecarboxamide may be prepared in the following manner: at 2 cm 3 of pyridine at 20 0 C are added 75 mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-Benzothiazol-2-amine and 20 ⁇ l of
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) acetamide may be prepared in the following manner: at 2 cm 3 of pyridine at 20 ° C. are added 0.276 cm 3 of acetic anhydride and 160 mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] thazolo [4,3-b] ] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine (1b).
- Phenyl (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] tertzolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) carbamate may be prepared as follows: to 200mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine (1b) in 5cm 3 of pyridine is added at 20 0 C, 0.13 cm 3 of phenyl chlorocarbonate.
- the reaction medium is stirred for 18 h at 20 ° C. and then the suspension is concentrated to dryness under reduced pressure.
- the oily brown residue obtained is taken up in 20 cm 3 of ethanol.
- the mixture is degassed by bubbling argon for 5 min at 20 ° C., then 5 mg of potassium dihydrogenphosphate are added in 0.2 cm 3 of water followed by 617 mg of DL-Dithiothreitol and 253 mg of 3-chloro-6- (cyclohexyloxy).
- [1,2,4] triazolo [4,3-b] pyhdazine (1c) After 23 hours under reflux, the red suspension is concentrated to dryness under reduced pressure.
- the residue is purified by dry deposition on Biotage Quad 25M (KP-SIL, 60, 32-63 ⁇ M) eluting with a gradient of 95: 5 to 85:15 of dichloromethane / (dichloromethane: 38 / methanol: 17 / aqueous ammonia: 2).
- the yellow solid obtained is washed with ether and with pentane. 218 mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -N- [2- (pyrrolidin-1-yl) are thus obtained.
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -2- methoxyacetamide can be prepared in a manner similar to Example 1a but from 200 mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine (1b) in 5cm 3 of pyridine with 0.165 cm 3 of methoxyacetyl chloride after 23h of reaction at 20 ° C.
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -N 2 N 2 -dimethylglycinamide can be prepared in a manner similar to Example 1a, but from 100 mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] tetrazolo [4,3-b] pyridazin).
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -3- methylbutanannide can be prepared in a manner similar to Example 1a but from 102 mg of 6 - ⁇ [6-
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -3- methoxypropanamide can be prepared in a manner similar to Example 1a but from 146 mg of 6 - ⁇ [6- (cyclohexyloxy) [1,2,4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine (1b) in 5cm 3 of pyridine with 0.191 cm 3 of 3-methoxypropanoyl chloride after 23h of reaction at 20 ° C.
- 6 - ⁇ [6- (cyclopentyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine a)
- the 6 - ⁇ [6 (cyclopentyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine can be prepared in a manner similar to Example 1b but from 889 mg of 3-chloro-6-
- N- (6 - ⁇ [6- (cyclopentyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) cyclopropanecarboxamide may be prepared in a manner similar to Example 1a but from 300 mg of 6 - ⁇ [6- (cyclopentyloxy) [1,2,4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ - 1, 3-benzothiazol-2-amine (11a) in 5 cm 3 of pyridine with 0.140 cm 3 of cyclopropane carboxylic acid chloride after 3 hours of reaction at 20 ° C.
- N- (6 - ⁇ [6- (cyclopentyloxy) [1,2,4] tetrazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) acetamide may be prepared in a manner similar to Example 1a but from 250 mg of 6 - ⁇ [6- (cyclopentyloxy) [1,2,4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ - 1, 3-benzothiazol-2-amine 11a in 5 cm 3 of pyridine with 2.5 cm 3 of acetic anhydride after 48h of reaction at 20 0 C.
- 6 - ⁇ [6- (cycloheptyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine can be prepared in a manner similar to Example 1b but starting from 249 mg of 3-chloro-6- (cycloheptyloxy) [1,2,4] triazolo [4,3-b] pyridazine (15b) in 5 cm 3 of degassed ethanol, 5 mg of potassium dihydrogenphosphate in 0.1 cm 3 of water, 432 mg of DL-dithiothreitol and 193 mg of 2-amino-1,3-benzothiazol-6-yl thiocyanate after 24 hours at 80 ° C. 260 mg is thus obtained from 6 - ⁇ [6-
- N- (6 - ⁇ [6- (cycloheptyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) acetamide may be prepared in a manner similar to Example 1a but from 85 mg of 6 - ⁇ [6- (cycloheptyloxy) [1,2,4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ - 1,3-benzothiazol-2-amine (16a) in 5 cm 3 of pyridine with 0.160 cm 3 of acetic anhydride after 24 hours of reaction at 20
- the N- (6 - ⁇ [6- (cyclohexylamino) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) acetamide may be prepared in a manner similar to Example 1a but from 150 mg of 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] -N-cyclohexyl [1,2,4] thazolo [4] , 3-b] pyridazin-6-amine in 1 cm 3 of pyridine with 0.5 cm 3 of acetic anhydride after 18h
- the resulting mixture is then stirred at 20 ° C. for 20 h and then extracted with 2x150 cm 3 of ethyl acetate.
- the organic phases are combined and then washed with 3X50 cm 3 of a saturated aqueous solution of sodium hydrogencarbonate.
- the organic phase obtained is dried over magnesium sulphate and then concentrated to dryness under reduced pressure. The residue is taken up in 50 cm 3 of water and then filtered off and dried under vacuum at 20 ° C.
- pyrimidazin-6-yl] amino ⁇ cyclohexyl may be prepared in a manner similar to Example 1a but from 300 mg of trans-4 - ( ⁇ 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] [1,2,4] tetrazolo [4,3-b] pyridazin-6-yl ⁇ amino ) cyclohexanol in 2.1 cm 3 of pyridine with 0,133cm 3 of the chloride of cyclopropanecarboxylic acid after 18 hours of reaction at 20 0 C.
- N- (6 - ⁇ [6- (cyclohexylamino) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) cyclopropanecarboxamide may be prepared in a manner similar to Example 1a but from 300 mg of 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] -N-cyclohexyl [1,2,4] thazolo [ 4,3-b] pyridazin-6-amine (18b) in 2.1 cm 3 of pyridine with 3 0,14cm chloride of cyclopropanecarboxylic acid, after 18h of reaction at 20 0 C.
- N- [6 - ( ⁇ 6 - [(trans-4-hydroxycyclohexyl) amino] [1,2,4] triazolo [4,3-b] pyridazin-3-yl ⁇ sulfanyl) 1,3-Benzothiazol-2-yl] acetamide can be prepared as follows: to a solution of 114 mg of trans-4 - ( ⁇ 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl) ] [1,2,4] thazolo [4,3-b] pyridazin-6-yl ⁇ amino) cyclohexanol (20b) in 2 cm 3
- N- [6 - ( ⁇ 6 - [(trans-4-hydroxycyclohexyl) amino] [1,2,4] triazolo [4,3-b] pyridazin-3-yl ⁇ sulfanyl) -1,3-benzothiazole 2-yl] cyclopropanecarboxamide can be prepared in a manner similar to Example 1a but from 300 mg of trans-4 - ( ⁇ 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] [1,2,4] triazolo [4,3-b] pyridazin-6-yl) amino) cyclohexanol (20b) in 3cm 3 of pyridine with 0.235cm 3 of cyclopropane carboxylic acid chloride, after 16h of reaction at 20 0 C.
- Example 25 N- (6 - ⁇ [6- (Cyclopropylamino) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) acetamide
- the N- (6 - ⁇ [6- (cyclopropylamino) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) acetamide may be prepared in a manner similar to Example 1a but from 300 mg of 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] -N-cyclopropyl [1,2,4] triazolo [4] , 3-b] pyridazin-6-amine (24a) in 2.1 cm 3 of pyridine with 1. 04 cm 3 of acetic anhydr
- 1,3-benzothiazol-2-yl) cyclopropanecarboxamide a) N- (6 - ⁇ [6- (Cyclopropylamino) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ - 1,3-Benzothiazol-2-yl) cyclopropanecarboxamide may be prepared in a manner similar to Example 1a but from 300 mg of 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] N-cyclopropyl [1,2,4] triazolo [4,3-b] py ⁇ dazin-6-amine (24a) in 3 cm 3 of pyridine with 0.16 cm 3 of cyclopropane carboxylic acid chloride, after 18 hours of reaction at 20 ° C.
- N- (6 - ⁇ [6- (cyclopropylamino) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -3-methoxypropanamide may be prepared in a manner similar to Example 1a but from 220 mg of 3 - [(2-amino-1,3-benzothiazol-6-yl) sulfanyl] -N-cyclopropyl [1,2,4] triazolo [4] , 3-b] py ⁇ dazin-6-amine (24a) in 7cm 3 of pyridine with 0.2 cm 3 of 3-methoxypropanoyl chloride after 18h of reaction at 20 ° C.
- Ethyl (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) carbamate can be prepared in the following way:
- MASS SPECTRUM Waters UPLC-SQD:
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -N 2 -cyclopropylglycinamide can be prepared in the following manner: at 280mg of 2-chloro-N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3 - yl] sulfanyl ⁇ -1,3-benzothiazol-2-y
- 6 - ⁇ [6- (cyclobutyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine a)
- the 6 - ⁇ [6 - (Cyclobutyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-amine can be prepared in a manner similar to Example 1b but starting from 1.07 g of 2-amino-1,3-benzothiazol-6-yl thiocyanate, 15 cm 3 of degassed ethanol, 20 mg of potassium dihydrogenphosphate in 0.1 cm 3 of water, 1 g.
- N- (6 - ⁇ [6- (cyclobutyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1, 3-Benzothiazol-2-yl) -2- (4-ethylpiperazin-1-yl) acetamide can be prepared in the following manner: a mixture of 273 mg of (4-ethylpiperazin-1-yl) acetic acid (commercial), 0.28cm 3 of diisopropyl ethylamine and 411 mg of O- (7-azabenzotriazol-1-yl) -N,
- N 2 -dialylglycinamide can be prepared in the following manner: a mixture of 827 mg of sodium (diethylamino) acetate (commercial) in 5.5 cm 3 of a 2N solution of hydrogen chloride in the The ether is stirred for 1 h at 20 ° C.
- the residue is taken up in water and the mixture is extracted with ethyl acetate and then evaporated to dryness.
- the residue is purified by dry deposition on silica and chromatographed on Biotage Quad 12/25 (KP-SIL, 6OA, 32-63 ⁇ M), eluting with a dichloromethane / methanol gradient of 100/0 to 98/2.
- MASS SPECTRUM Waters UPLC-SQD:
- racemic pyhdazine can be prepared in a manner similar to that described in Example 1c but from 0.628 g of a 1/1 mixture of racemic cis- and trans-3-methylcyclohexanol in solution in 6 cm 3 tetrahydrofuran under an argon stream to which is added at a temperature of 0 0 C, 0.220 g of 60% sodium hydride in the oil.
- the reaction medium is maintained at a temperature in the region of 0 ° C. for 15 minutes and then 0.650 g of 3,6-dichloro [1,2,4] thazolo [4,3-b] pyridazine is added.
- 10 cm 3 of a saturated aqueous ammonium chloride solution and 20 cm 3 of ethyl acetate are added.
- the organic phase is washed successively with 2 times 10 cm 3 of distilled water and 15 cm 3 of a saturated solution of sodium chloride and is then dried over anhydrous magnesium sulfate, filtered and concentrated to dryness under reduced pressure.
- N- (6-sulfanyl-1,3-benzothiazol-2-yl) cyclopropanecarboxamide can be prepared in a manner similar to that described in Example 2b but from 14.0 g of 2 - [(cyclopropylcarbonyl) thiocyanate ) amino] -1,3-benzothiazol-6-yl, 22.44 g of DL-dithiothreitol, a solution of 0.235 g of potassium dihydrogenphosphate in 60 cm 3 of distilled water and 450 cm 3 of ethanol.
- the solid formed is filtered on a VF3 filter and then washed with 5 times 70 cm 3 of ice water before drying in an oven under reduced pressure (2.7 kPa) at 40 ° C. for 10 h to give 19 g of 2 - [( cyclopropylcarbonyl) amino] -1,3-benzothiazol-6-yl as a pink solid whose characteristics are as follows:
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -3- (Piperidin-1-yl) azetidine-1-carboxamide can be prepared in a manner similar to Example 5 but from 185 mg of (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] thazolo [ Phenyl 4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) carbamate (4) in 10cm 3 of THF and 10cm 3 of DMF with 75mg of 1 - (azetidin) dihydrochloride.
- MASS SPECTRUM Electron emission on WATERS UPLC - SQD: [M + H] +: m / z 565; [M-H] -: m / z 563.
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -2- oxa-6-azaspiro [3.3] heptane-6-carboxamide can be prepared in a manner similar to that described in Example 5 but from 150 mg of (6 - ⁇ [6- (cyclohexyloxy) [1, 2, 4] thazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) phenyl carbamate (4), 65 mg of mono oxalate of 2-oxa-6-aza-spiro [3.3] heptane, 0.144 cm 3 of triethylamine and 10 cm 3 of tetrahydrofuran. After stirring for 15 hours at a temperature in the
- oxalate monooxalate of 2-oxa-6-aza-spiro [3.3] heptane can be prepared as described by Georg Wunschik, Mark Rogers-Evans, Andreas Buckl, Maurizio
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -3- (morpholin-4-yl) azetidine-1-carboxamide can be prepared in a manner similar to Example 5 but from 182 mg of (6- ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [ Phenyl 4,3-b] pyridazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) carbamate (4) in 10cm 3 THF, 106mg 4- (azetidin-3-yl) dihydrochloride ) morpholine and 0.167 cm 3 of triethylamine, after 22 hours of reaction at 20 ° C.
- N- (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] triazolo [4,3-b] pyhdazin-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) -3- methoxyazetidine-1-carboxamide can be prepared in a manner similar to Example 5 but from 192 mg of (6 - ⁇ [6- (cyclohexyloxy) [1,2,4] thazolo [4,3-b] pyridazine Phenyl-3-yl] sulfanyl ⁇ -1,3-benzothiazol-2-yl) carbamate (4) in 5 cm 3 of dimethylformamide, 69 mg of 3-methoxyazetidine hydrochloride and 0.078 cm 3 of the methylamine after 20 hours of reaction with 20 0 C.
- MASS SPECTRUM Electron-ray on WATERS UPLC - SQD: [M + H] +: m / z 498; [M-H] -: m / z 496.
- Example 78 Pharmaceutical composition Tablets having the following formula were prepared:
- Examples 1 and 4 are taken as examples of a pharmaceutical preparation, this preparation can be carried out if desired with other products as examples in the present application.
- Recombinant His-Tev-MET (956-1390) DNA in pFastBac (Invitrogen) is transfected into insect cells and after several viral amplification steps, the final baculovirus stock is tested for protein expression. interest.
- the SF21 cell cultures are harvested by centrifugation and the cell pellets are stored at -80 ° C. Purification:
- the cell pellets are resuspended in lysis buffer (buffer A [50 mM HEPES, pH 7.5, 250 mM NaCl, 10% glycerol, 1 mM TECP] + Roche Diagnostics protease inhibitor cocktail without EDTA, ref. 1873580), stirred at 4 ° C. until homogeneous, then mechanically lysed using a "Dounce" type apparatus.
- buffer A 50 mM HEPES, pH 7.5, 250 mM NaCl, 10% glycerol, 1 mM TECP] + Roche Diagnostics protease inhibitor cocktail without EDTA, ref. 1873580
- the lysing supernatant is incubated for 2 hours at 4 ° C with Nickel Chelate resin (His-Trap 6 Fast Flow TM, GE HealthCare). After washing with 20 volumes of Tp A, the suspension is packaged in a column, and the proteins are eluted by a gradient of buffer B (TpA + 290 mM imidazole).
- the fractions containing the protein of interest in view of the electrophoretic analysis are pooled, concentrated by Ultrafiltration (cut-off 1 OkDa) and injected on an exclusion chromatography column (Superdex TM 200, GE HealthCare). balanced in buffer A. After enzymatic cleavage of the Histidine tag, the protein is reinjected onto a new IMAC Nickel Chelate chromatography column (His-Trap 6 Fast Flow TM, GE HealthCare) equilibrated in Buffer A. The fractions eluted by a buffer B gradient and containing the protein after electrophoresis (SDS PAGE), are finally collected and stored at -80 ° C.
- the preceding fractions are incubated for 1 h at room temperature after addition of 2 mM ATP, 2 mM MgCl 2, and Na 3 VO 4. 4 mM.
- the reaction mixture is injected onto a HiPrep desalting column (GE HealthCare) previously equilibrated with 4mM A + Na3VO4 buffer, the fractions containing the protein of interest (SDS PAGE analysis) are pooled. and stored at -80 ° C.
- the phosphorylation level is verified by mass spectrometry (LC-MS), and by peptide mapping.
- Test A HTRF MET assay in 96-well format
- final 5 nM MET is incubated in the presence of the test molecule (for a final concentration range of 0.17 nM to 10 ⁇ M, final DMSO 3%) in MOPS 1 OmM buffer pH 7.4, DTT 1 mM, Tween 20 0.01%.
- the reaction is initiated by the substrate solution to obtain the final concentrations of poly- (GAT) 1 ⁇ g / ml, 10 ⁇ M ATP and 5mM MgCl 2.
- the reaction is stopped by a 30 ⁇ l mix to obtain a final solution of 50 mM Hepes pH 7.5, 50 mM potassium fluoride, 0.1% BSA and 133 mM EDTA in the presence of 80 ng Streptavidin. 61 SAXLB Cis-Bio Int. and 18ng anti-Phosphotyrosine Mab PT66-Europium Cryptate per well. After 2 hours incubation at room temperature, the reading is made at 2 wavelengths 620 nm and 665 nm on a reader for the TRACE / HTRF technique and the% inhibition is calculated according to the 665/620 ratios.
- Test B Inhibition of MET autophosphorylation; ELISA technique (pppY1230,1234,1235) a) Cell lysates: Inoculate MKN45 cells in 96-well plate (CeII coat BD polylysine) at 20,000 cells / well under 200 ⁇ l in RPMI medium + 10% FCS + 1% L-glutamine. Allow 24 hours to adhere to the incubator.
- the cells are treated the day after seeding with the products at 6 concentrations in duplicate for 1 h. At least 3 control wells are treated with the same amount of final DMSO.
- Lysis buffer 1 OmM Tris, pH 7.4 HCl, 10 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X- 100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, 20mM NaF, 2mM Na3VO4, 1mM PMSF and anti protease cocktail.
- kit plate In each well of the kit plate, add 70 ⁇ l of kit dilution buffer + 30 ⁇ l of cell lysate or 30 ⁇ l of lysis buffer for the blanks. Incubate for 2h with gentle shaking at room temperature.
- kit wash buffer Incubate with 10 ⁇ l of anti-phospho MET antibody for 1h at room temperature.
- kit wash buffer Put 100 ⁇ L of chromogen and incubate 30minutes in the dark at room temperature.
- Test C Measurement of Cell Proliferation Using 14C-Thymidine
- the cells are seeded in 96-well Cytostar plates at 180 ⁇ l for 4 hours at 37 ° C. and 5% CO 2: HCT116 cells at a rate of 2500 cells per well in DMEM medium + 10% fetal calf serum + 1% L Glutamine and MKN45 cells at the rate of 7500 cells per well in RPMI medium + 10% fetal calf serum + 1% L-Glutamine.
- HCT116 cells at a rate of 2500 cells per well in DMEM medium + 10% fetal calf serum + 1% L Glutamine
- MKN45 cells at the rate of 7500 cells per well in RPMI medium + 10% fetal calf serum + 1% L-Glutamine.
- the products are added under 10 ⁇ l in 20-fold concentrated solution according to the dilution method mentioned for the ELISA.
- the products are tested at 10 concentrations in duplicate from 1000OnM to 0.3nM with a pitch of 3.
- results obtained by this test B for the products of formula (I) as examples in the experimental part are such that IC50 less than 10 microM and in particular to i microM.
- results obtained for the exemplary products in the experimental part are given in the table of pharmacological results below, as follows: for test A, the sign + corresponds to less than 50 nm and the sign ++ corresponds to less than 100 nm. . for test B the sign + corresponds to less than 50OnM and the sign ++ corresponds to less than 10OnM. for the C test the + sign corresponds to less than 10 microM and the sign ++ corresponds to less than I microM.
- Ra represents a radical -O-cycloalkyl, or a radical -NH-cycloalkyl all optionally substituted
- X represents S, SO or SO2;
- A represents NH or S;
- W represents a hydrogen atom; an alkyl radical optionally substituted with alkoxy, heterocycloalkyl or NR3R4; or the radical COR in which R represents:
- a cycloalkyl radical or an alkyl radical, optionally substituted by a halogen atom or a cycloalkyl, NR3R4, alkoxy, hydroxy, phenyl, heteroaryl or heterocycloalkyl radical, themselves optionally substituted;
- R1 and R2 are such that one of R1 and R2 represents a hydrogen atom, a cycloalkyl radical or an alkyl radical and the other of R1 and R2 represents a hydrogen atom,
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011548750A JP2012517407A (ja) | 2009-02-06 | 2010-02-04 | 6−(6−o−シクロアルキル−または6−nh−シクロアルキル−トリアゾロピリダジン−スルファニル)ベンゾチアゾールおよびベンゾイミダゾールの誘導体、この調製、薬物としてのこの使用、ならびにmet阻害薬としてのこの使用 |
CA2751525A CA2751525A1 (fr) | 2009-02-06 | 2010-02-04 | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met |
AU2010212231A AU2010212231A1 (en) | 2009-02-06 | 2010-02-04 | Derivatives of 6-(6-O-cycloalkyl or 6-NH-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as MET inhibitors |
SG2011056470A SG173558A1 (en) | 2009-02-06 | 2010-02-04 | Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
MX2011008312A MX2011008312A (es) | 2009-02-06 | 2010-02-04 | Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiri dazina-sulfanil) benzotiazoles y bencimidazoles: preparacion, aplicacion como medicamentos y uso como inhibidores de met. |
BRPI1011354A BRPI1011354A2 (pt) | 2009-02-06 | 2010-02-04 | derivados de 6-(6-0-ciclo alquil ou 6-nh-ciclo alquil-triazolo piridazina sulfanil) benzotiazóis e benzimadazóis: preparo, aplicação como medicamentos e utilização como inibidores de met |
EA201171010A EA201171010A1 (ru) | 2009-02-06 | 2010-02-04 | Производные 6-(6-o-циклоалкил- или 6-nh-циклоалкилтриазолопиридазинсульфанил)бензотиазолов и бензимидазолов: способ получения, применение в качестве лекарственных средств и применение в качестве ингибиторов met |
CN2010800150530A CN102388029A (zh) | 2009-02-06 | 2010-02-04 | 6-(6-o-环烷基-或6-nh-环烷基-三唑并哒嗪-硫基)苯并噻唑和苯并咪唑的衍生物、其制备方法、其作为药物的用途以及其作为met抑制剂的用途 |
MA34147A MA33102B1 (fr) | 2009-02-06 | 2010-02-04 | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met |
EP10708277A EP2393790A1 (fr) | 2009-02-06 | 2010-02-04 | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met |
IL214407A IL214407A0 (en) | 2009-02-06 | 2011-08-02 | Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl)benzothiazoles and benzoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0900510A FR2941949B1 (fr) | 2009-02-06 | 2009-02-06 | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
FR09/00510 | 2009-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010089506A1 true WO2010089506A1 (fr) | 2010-08-12 |
Family
ID=40863635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2010/050177 WO2010089506A1 (fr) | 2009-02-06 | 2010-02-04 | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2393790A1 (ru) |
JP (1) | JP2012517407A (ru) |
KR (1) | KR20110126660A (ru) |
CN (1) | CN102388029A (ru) |
AR (1) | AR075248A1 (ru) |
AU (1) | AU2010212231A1 (ru) |
BR (1) | BRPI1011354A2 (ru) |
CA (1) | CA2751525A1 (ru) |
CO (1) | CO6400222A2 (ru) |
EA (1) | EA201171010A1 (ru) |
FR (1) | FR2941949B1 (ru) |
IL (1) | IL214407A0 (ru) |
MA (1) | MA33102B1 (ru) |
MX (1) | MX2011008312A (ru) |
SG (1) | SG173558A1 (ru) |
TW (1) | TW201040187A (ru) |
UY (1) | UY32419A (ru) |
WO (1) | WO2010089506A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003028721A2 (en) | 2001-09-26 | 2003-04-10 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
WO2007075567A1 (en) * | 2005-12-21 | 2007-07-05 | Janssen Pharmaceutica, N.V. | Triazolopyridazines as tyrosine kinase modulators |
WO2007138472A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
WO2008008539A2 (en) * | 2006-07-14 | 2008-01-17 | Amgen Inc. | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
WO2008051808A2 (en) * | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
WO2009056692A2 (fr) * | 2007-08-09 | 2009-05-07 | Sanofi-Aventis | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
-
2009
- 2009-02-06 FR FR0900510A patent/FR2941949B1/fr not_active Expired - Fee Related
-
2010
- 2010-02-04 JP JP2011548750A patent/JP2012517407A/ja not_active Withdrawn
- 2010-02-04 EA EA201171010A patent/EA201171010A1/ru unknown
- 2010-02-04 MX MX2011008312A patent/MX2011008312A/es not_active Application Discontinuation
- 2010-02-04 MA MA34147A patent/MA33102B1/fr unknown
- 2010-02-04 AU AU2010212231A patent/AU2010212231A1/en not_active Abandoned
- 2010-02-04 CA CA2751525A patent/CA2751525A1/fr not_active Abandoned
- 2010-02-04 BR BRPI1011354A patent/BRPI1011354A2/pt not_active IP Right Cessation
- 2010-02-04 CN CN2010800150530A patent/CN102388029A/zh active Pending
- 2010-02-04 KR KR1020117020676A patent/KR20110126660A/ko not_active Application Discontinuation
- 2010-02-04 EP EP10708277A patent/EP2393790A1/fr not_active Withdrawn
- 2010-02-04 SG SG2011056470A patent/SG173558A1/en unknown
- 2010-02-04 WO PCT/FR2010/050177 patent/WO2010089506A1/fr active Application Filing
- 2010-02-05 AR ARP100100316A patent/AR075248A1/es unknown
- 2010-02-05 TW TW099103558A patent/TW201040187A/zh unknown
- 2010-02-05 UY UY0001032419A patent/UY32419A/es not_active Application Discontinuation
-
2011
- 2011-08-02 IL IL214407A patent/IL214407A0/en unknown
- 2011-08-05 CO CO11099121A patent/CO6400222A2/es not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003028721A2 (en) | 2001-09-26 | 2003-04-10 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
WO2007075567A1 (en) * | 2005-12-21 | 2007-07-05 | Janssen Pharmaceutica, N.V. | Triazolopyridazines as tyrosine kinase modulators |
WO2007138472A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
WO2008008539A2 (en) * | 2006-07-14 | 2008-01-17 | Amgen Inc. | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
WO2008051808A2 (en) * | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
WO2009056692A2 (fr) * | 2007-08-09 | 2009-05-07 | Sanofi-Aventis | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
Non-Patent Citations (7)
Title |
---|
ANONYMOUS: "CHEMICAL BOOK :2-amino-6-benzothiazolethiol", INTERNET CITATION, 1 January 2007 (2007-01-01), pages 1, XP002523730, Retrieved from the Internet <URL:http://www.chemicalbook.com/ChemicalProductProperty_EN_CB81296260.htm> [retrieved on 20090415] * |
D. T. WITIAK, J. MED. CHEM., vol. 28, 1985, pages 1228 |
D.D . DESMARTEAU; V. MONTANARI, CHEM LETT, 2000, pages 1052 |
GEORG WUITSCHIK; MARK ROGERS-EVANS; ANDREAS BUCKL; MAURIZIO BERNASCONI; MORITZ M_RKI; THIERRY GODEL; HOLGER FISCHER; BJ"RN WAGNER;, ANGEW. CHEM. INT. ED., vol. 47, 2008, pages 4512 - 4515 |
JAGABANDHU DAS, J. MED. CHEM., vol. 49, 2006, pages 6819 - 6832 |
N. XI ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 5211 - 5217 |
U. SCHOPFER, TETRAHEDRON, vol. 57, 2001, pages 3069 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
US9062045B2 (en) | 2011-09-15 | 2015-06-23 | Novartis Ag | Triazolopyridine compounds |
US9474762B2 (en) | 2011-09-15 | 2016-10-25 | Novartis Ag | Triazolopyridine compounds |
Also Published As
Publication number | Publication date |
---|---|
KR20110126660A (ko) | 2011-11-23 |
EA201171010A1 (ru) | 2012-03-30 |
MX2011008312A (es) | 2011-11-02 |
MA33102B1 (fr) | 2012-03-01 |
EP2393790A1 (fr) | 2011-12-14 |
AU2010212231A1 (en) | 2011-08-25 |
FR2941949B1 (fr) | 2011-04-01 |
JP2012517407A (ja) | 2012-08-02 |
IL214407A0 (en) | 2011-09-27 |
SG173558A1 (en) | 2011-09-29 |
FR2941949A1 (fr) | 2010-08-13 |
AR075248A1 (es) | 2011-03-16 |
UY32419A (es) | 2010-09-30 |
CA2751525A1 (fr) | 2010-08-12 |
CO6400222A2 (es) | 2012-03-15 |
TW201040187A (en) | 2010-11-16 |
BRPI1011354A2 (pt) | 2019-09-24 |
CN102388029A (zh) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2178881B1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
EP2318414A2 (fr) | Derives imidazo [1,2-a] pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation comme inhibiteurs de met | |
EP2318382A1 (fr) | NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
WO2009087305A1 (fr) | Derives de 6-aryl/heter0alkyl0xy benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet | |
EP2393793A1 (fr) | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
WO2010089508A1 (fr) | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
WO2011121223A1 (fr) | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
CA2620857A1 (fr) | Derives de benzimidazoles et benzothiazoles et leur utilisation en tant qu'inhibiteurs de kinases notamment de met | |
WO2010089507A1 (fr) | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
EP2393790A1 (fr) | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
FR2919870A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet | |
FR2933981A1 (fr) | NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
FR2958292A1 (fr) | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
FR2929613A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080015053.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10708277 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3090/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 594360 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 214407 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011001882 Country of ref document: CL Ref document number: 2751525 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011548750 Country of ref document: JP Ref document number: 11099121 Country of ref document: CO Ref document number: 12011501582 Country of ref document: PH Ref document number: MX/A/2011/008312 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010708277 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010212231 Country of ref document: AU Date of ref document: 20100204 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117020676 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201171010 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1011354 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1011354 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110805 |